Exicure, Inc. (XCUR)

NCM – Real vaqt narxi. Valyuta: USD

3.24

-0.04 (-1.22%)

Yopilishda: May 12, 2026, 4:00 PM EDT

3.14

-0.10 (-3.09%)

Bozor oldidan: May 13, 2026, 4:01 AM EDT

22.04.2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.

02.04.2026

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice: TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF EXICURE, INC.

25.03.2026

Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.

25.03.2026

Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.

05.02.2026

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant

21.01.2026

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 4-7, 2026, in Salt Lake City, UT.

09.12.2025

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Exicure, Inc. (NASDAQ: XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.

Videolar

No Data

There is no data to display

Press-relizlar

22.04.2026

Exicure, Inc. (XCUR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Exicure, Inc. (XCUR)

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Videolar

No Data

Press-relizlar

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Videolar

No Data

Press-relizlar

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Search stocks

Exicure, Inc. (XCUR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Exicure, Inc. (XCUR)

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Videolar

No Data

Press-relizlar

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Videolar

No Data

Press-relizlar

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results